Enrico Mihich

Summary

Affiliation: Roswell Park Cancer Institute
Country: USA

Publications

  1. ncbi Seventeenth Annual Pezcoller Symposium: molecular understanding of solid tumors
    Enrico Mihich
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cancer Res 65:11251-4. 2005
  2. ncbi Cellular immunity for cancer chemoimmunotherapy--an overview
    Enrico Mihich
    Grace Cancer Drug Center, Rosswell Park Cancer Institute, New York State Department of Health, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Cancer Immunol Immunother 52:661-2. 2003
  3. ncbi Cancer therapeutics: personal experiences and future perspectives
    Enrico Mihich
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Biol Ther 3:911-5. 2004
  4. ncbi Sixteenth Annual Pezcoller Symposium: stem cells and epigenesis in cancer
    Enrico Mihich
    Pharmacology and Therapeutics Department, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Res 64:8474-7. 2004
  5. ncbi Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice
    Andrew Ewens
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Res 66:5419-26. 2006
  6. ncbi Thirteenth annual pezcoller symposium: focusing analytical tools on complexity in cancer
    Enrico Mihich
    Pharmacology and Therapeutics Department, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Res 62:3883-7. 2002
  7. ncbi Fifteenth annual Pezcoller symposium: molecular in vivo visualization of cancer cells
    Enrico Mihich
    Pharmacology and Therapeutics Department, Roswell Park Cancer Institute, Buffalo, New York, USA
    Cancer Res 64:2929-33. 2004
  8. ncbi Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells
    Peter Ujhazy
    Department of Pharmacology and Therapeutics, Grace Cancer Drug Center, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Cancer Immunol Immunother 52:463-72. 2003
  9. ncbi International symposium on tumour escape and its determinants: meeting report
    Kurt S Zanker
    Institute of Immunology, University Witten Herdecke
    Cancer Immunol Immunother 55:229-33. 2006
  10. ncbi Fourteenth Annual Pezcoller Symposium: the novel dichotomy of immune interactions with tumors
    Douglas Hanahan
    University of California at San Francisco, San Francisco, California 94143, USA
    Cancer Res 63:3005-8. 2003

Research Grants

  1. CANCER CHEMOTHERAPY AND IMMUNOLOGIC EFFECTS
    Enrico Mihich; Fiscal Year: 2001
  2. Chemoimmunoprevention of prostate and breast cancer
    Enrico Mihich; Fiscal Year: 2004

Collaborators

Detail Information

Publications13

  1. ncbi Seventeenth Annual Pezcoller Symposium: molecular understanding of solid tumors
    Enrico Mihich
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cancer Res 65:11251-4. 2005
  2. ncbi Cellular immunity for cancer chemoimmunotherapy--an overview
    Enrico Mihich
    Grace Cancer Drug Center, Rosswell Park Cancer Institute, New York State Department of Health, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Cancer Immunol Immunother 52:661-2. 2003
  3. ncbi Cancer therapeutics: personal experiences and future perspectives
    Enrico Mihich
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Biol Ther 3:911-5. 2004
  4. ncbi Sixteenth Annual Pezcoller Symposium: stem cells and epigenesis in cancer
    Enrico Mihich
    Pharmacology and Therapeutics Department, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Res 64:8474-7. 2004
    ..Epigenetic control mechanisms affecting gene expression with emphasis on DNA methylation and histone function were considered. Therapeutic strategies stemming from the knowledge acquired in the basic topics discussed also were outlined...
  5. ncbi Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice
    Andrew Ewens
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Res 66:5419-26. 2006
    ..The efficacy of this nontoxic treatment and the potential to be able to predict which individual is responding to treatment are characteristics that make this chemoimmunotherapy attractive for clinical testing...
  6. ncbi Thirteenth annual pezcoller symposium: focusing analytical tools on complexity in cancer
    Enrico Mihich
    Pharmacology and Therapeutics Department, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Res 62:3883-7. 2002
    ....
  7. ncbi Fifteenth annual Pezcoller symposium: molecular in vivo visualization of cancer cells
    Enrico Mihich
    Pharmacology and Therapeutics Department, Roswell Park Cancer Institute, Buffalo, New York, USA
    Cancer Res 64:2929-33. 2004
    ....
  8. ncbi Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells
    Peter Ujhazy
    Department of Pharmacology and Therapeutics, Grace Cancer Drug Center, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Cancer Immunol Immunother 52:463-72. 2003
    ..These data demonstrate that a single DOX injection induces specific effects in PEC and, as a consequence, increases the tumoricidal potential of cells of the macrophage and natural killer types...
  9. ncbi International symposium on tumour escape and its determinants: meeting report
    Kurt S Zanker
    Institute of Immunology, University Witten Herdecke
    Cancer Immunol Immunother 55:229-33. 2006
  10. ncbi Fourteenth Annual Pezcoller Symposium: the novel dichotomy of immune interactions with tumors
    Douglas Hanahan
    University of California at San Francisco, San Francisco, California 94143, USA
    Cancer Res 63:3005-8. 2003
    ..The symposium was concluded with an overall discussion focused on basic questions related to the capability of immunity to exert tumor-favoring or antitumor effects depending on conditions determined by both tumor and host functions...
  11. ncbi Development of novel cancer chemopreventive agents in Europe--neglected Cinderella or rising phoenix? A critical commentary. ESF Workshop on Cancer Chemoprevention, DKFZ, Heidelberg, September 18-20, 2005
    Clarissa Gerhauser
    German Cancer Research Center, Toxicology and Cancer Risk Factors, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
    Eur J Cancer 42:1338-43. 2006
    ..Overall the workshop aimed at raising awareness among European clinical and laboratory researchers of the importance of the development of novel, efficacious and safe cancer preventive agents...
  12. ncbi Eighteenth annual pezcoller symposium: tumor microenvironment and heterotypic interactions
    Robert Weinberg
    Whitehead Institute for Biomedical Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
    Cancer Res 66:11550-3. 2006
    This symposium was held in Trento, Italy, from June 27 to 29, 2006, and was co-chaired by Robert Weinberg and Enrico Mihich. The interactions between tumor cells and their microenvironment were discussed with particular emphasis on their ..
  13. ncbi Nineteenth Annual Pezcoller Symposium: hypothesis-driven clinical investigation in cancer
    William G Kaelin
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Res 67:11102-5. 2007
    This symposium was held in Trento, Italy, from June 14 to 16, 2007, and was co chaired by William G. Kaelin, Enrico Mihich, and Charles L. Sawyers...

Research Grants4

  1. CANCER CHEMOTHERAPY AND IMMUNOLOGIC EFFECTS
    Enrico Mihich; Fiscal Year: 2001
    ..abstract_text> ..
  2. Chemoimmunoprevention of prostate and breast cancer
    Enrico Mihich; Fiscal Year: 2004
    ..It is expected that this R0-3 will be followed by an R0-1 based on the preliminary results obtained herein. ..